Breaking News

Catalent, Edenbridge Pharma Enter Zydis Formulation Supply Agreement

Novel formulation of glycopyrrolate will use Catalent’s Zydis ODT delivery technology for adjunctive therapy for the treatment of peptic ulcer.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Catalent, a global provider of delivery technologies, development, and manufacturing services for drugs, biologics, cell and gene therapies, and consumer health products, has signed a commercial supply agreement with Edenbridge Pharmaceuticals, LLC, for a novel formulation of glycopyrrolate using Catalent’s Zydis orally disintegrating tablet (ODT) delivery technology intended for use as adjunctive therapy in the treatment of patients with peptic ulcer. The Zydis formulation of glycopyrrolate is ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters